Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nemorosone is a polycyclic polyprenylated acylphloroglucinol (PPAP) isolated from the flower resin of *Clusia rosea*. It is being investigated as a potential anti-cancer lead compound, particularly for chemoresistant pancreatic cancer. Its mechanism of action involves the induction of endoplasmic reticulum (ER) stress and the activation of the unfolded protein response (UPR) pathway, specifically through the up-regulation of GADD153 (DDIT3). This leads to rapid depletion of ER calcium stores, depolarization of the mitochondrial membrane, and subsequent activation of the intrinsic apoptotic pathway. Unlike its structural relative hyperforin, nemorosone does not significantly induce CYP3A4 expression, suggesting a lower risk for drug-drug interactions in combination therapy settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nemorosone.